Retrospective database analysis of the prevention of venous thromboembolism with low-molecular-weight heparin in acutely III medical inpatients in community practice

Clinical Therapeutics

Volumn 26, Issue 3, 2004, Pages 419-430

  McGarry, Lisa J ^a   Thompson, David ^a  

^a i3 Global   (Canada)

Author keywords

Embolism and thrombosis; Heparin; Low molecular weight; Outcomes research; Prevention

Indexed keywords

ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ACUTE DISEASE; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; COMMUNITY CARE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; FEMALE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION; ISCHEMIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEOPLASM; OUTCOMES RESEARCH; PROPHYLAXIS; RESPIRATORY TRACT DISEASE; VENOUS THROMBOEMBOLISM;

EID: 1842450657     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)90038-0     Document Type: Article

References (22)

1. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worchester DVT Study. Arch Intern Med. 1991;151:933-938.
2. Diamond PT, Macciocchi SN. Predictive power of clinical symptoms in patients with presumptive deep venous thrombosis. Am J Phys Med Rehabil. 1997;76:49-51.
3. Mandelli V, Schmid C, Zogno C, Morpurgo M. "False negatives" and "false positives" in acute pulmonary embolism: A clinical-postmortem comparison. Cardiologia. 1997;42:205-210.
4. Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest. 1995;108:978-981.
5. Lucchi M, Bilancini S. Is clinical diagnosis of deep-vein thrombosis really unreliable [in French]? J Mal Vasc. 1993;18:303-305.
6. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest. 2001;119(Suppl):132S-175S.
7. Anderson FA Jr, Hirsh J, White K, Fitzgerald RH Jr. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: Findings from the hip and knee registry. Chest. 2003;124(Suppl):349S-356S.
8. Caprini JA, Arcelus J, Sehgal LR, et al. The use of low molecular weight heparins for the prevention of post-operative venous thromboembolism in general surgery. A survey of practice in the United States. Int Angiol. 2002;21:78-85.
9. Mesko JW, Brand RA, Iorio R, et al. Venous thromboembolic disease management patterns in total hip arthroplasty and total knee arthroplasty patients: A survey of AAHKS membership. J Arthroplasty. 2001;16:679-688.
10. Tapson VF, Decousus H, Piovella F, et al. A multinational observational cohort study in acutely ill medical patients of practices in prevention of venous thromboembolism: Findings of the international medical prevention registry on venous thromboembolism (IMPROVE). Blood. 2003;102:321a. Abstract.
11. Dahan R, Houlbert D, Caulin C, et al. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: A randomized double-blind trial. Haemostasis. 1986;16:159-164.
12. Harenberg J, Kallenbach B, Martin U, et al. Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. Thromb Res. 1990;59:639-650.
13. Bergmann JF, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thromb Haemost. 1996;76:529-534.
14. Lechler E, Schramm W, Flosbach CW. The venous thrombotic risk in non-surgical patients: Epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The PRIME Study Group. Haemostasis. 1996;26(Suppl 2):49-56.
15. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341:793-800.
16. Fraisse F, Holzapfel L, Couland JM, et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med. 2000;161:1109-1114.
17. Kleber F-X, Witt C, Vogel G, et al, for THE-PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J. 2003;145:614-621.
18. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular- weight heparins: A meta-analysis of randomised clinical trials. Thromb Haemost. 2000;83:14-19.
19. Castillo LA, Hopkins CA, Aaron WS, eds. St. Anthony's ICD-9-CM Code Book for Physician Compliance. Reston, Va: St. Anthony; 1998.
20. US Dept of Health and Human Services, Office for Civil Rights. HIPAA Medical Privacy - National Standards to Protect the Privacy of Personal Health Information. Available at: http://www.hhs.gov/ocr/hipaa/finalreg.html. Accessed December 15, 2003.
21. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research: Principles and Quantitative Methods. Belmont, Calif: Lifetime Learning; 1982.
22. US Census Bureau. United States Census 2000. Available at: http://www.census.gov. Accessed March 8, 2003.